• Cranshire Capital has bought into Cell Therapeutics. The company announced today that it received $15M from the investment fund with Rodman & Renshaw acting as placement agent. [Xconomy]

• Othera Pharmaceuticals has reported positive Phase 2 results from its dry AMD study using an eyedrop formulation of the antioxidant Tempol. [Pharmaceutical Business Review]

• RegeneRx has raised $600,000 and imlemeted a 35% reduction in salaries of almost all executives and staff. [PR Inside]

• Nanobac Pharmaceuticals and Eureka Genomics sign merger agreement. I know, I know: who the heck is Nanobac? Eureka? [BioSpace]

• Canadian CRO PharmEng has also axed some of its directors, and implemented a 50% salary reduction for its CEO. [TechFinance]

• Mylan wants to sell a generic Xeloda, Roche sues. [Bloomberg]

And that’s that…slow today…zzzzzz

Image from Cell Therapeutics

Related Posts